...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >Management of iatrogenic renal arteriovenous fistula and renal arterial pseudoaneurysm by transarterial embolization: A single center analysis and outcomes
【24h】

Management of iatrogenic renal arteriovenous fistula and renal arterial pseudoaneurysm by transarterial embolization: A single center analysis and outcomes

机译：经动脉栓塞治疗医源性肾动静脉瘘和肾动脉假性动脉瘤：单中心分析和结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The purpose of this study was to evaluate the efficacy and safety of transarterial embolization (TAE) for iatrogenic renal arterial pseudoaneurysm and arteriovenous fistula at our center. Our retrospective analysis included 27 patients who received TAE for iatrogenic renal arterial pseudoaneurysm and arteriovenous fistula between January 2006 and January 2016. Data on demographics, type of minimally invasive renal procedures, clinical manifestation, imaging features, embolization procedure, and perioperative details were collected. The technical and clinical success rates were analyzed. Furthermore, the changes in serum creatinine and eGFR before and after embolization were recorded and compared by t test. The median time between iatrogenic renal injury and TAE was 3 days (range, 0–110 days), with most patients (24/27, 88.9%) receiving TAE within 14 days. Only 1 patient was diagnosed with renal artery pseudoaneurysm 110 days after laproscopic partial nephrectomy. The technical and clinical success rates were 100% and 96.3%, respectively, with 1 patient requiring a second embolotherapy at the third postoperative day. No other patient required additional endovascular or surgical intervention due to recurrent hemorrhage. The mean serum creatinine before TAE was 92.8 ± 25.3 μmol/L and after TAE, 96.1 ± 27.7 μmol/L ( P = .095). The eGFR of pre- and postembolization was 75.2 ± 26.5 mL/min/1.73 m2 and 72.5 ± 26.2 mL/min/1.73 m2 ( P = .16). No severe complications were observed during follow-up. This retrospective review demonstrated that TAE for the treatment of iatrogenic renal artery pseudoaneurysm and/or arteriovenous fistula was safe and associated with high technical and clinical success rate.
机译：这项研究的目的是评估经中心动脉栓塞术（TAE）对医源性肾动脉假性动脉瘤和动静脉瘘的有效性和安全性。我们的回顾性分析包括2006年1月至2016年1月之间因医源性肾动脉假性动脉瘤和动静脉瘘而接受TAE的27例患者。收集了人口统计学，微创肾脏手术类型，临床表现，影像学特征，栓塞手术和围手术期细节的数据。分析了技术和临床成功率。此外，栓塞前后血清肌酐和eGFR的变化被记录并通过t检验进行比较。医源性肾损伤与TAE之间的中位时间为3天（范围：0-110天），大多数患者（24 / 27，88.9％）在14天内接受TAE。腹腔镜部分肾切除术后110天，只有1例患者被诊断为肾动脉假性动脉瘤。技术和临床成功率分别为100％和96.3％，其中一名患者在术后第三天需要第二次栓塞治疗。没有其他患者因复发性出血而需要额外的血管内或手术干预。 TAE前的平均血清肌酐为92.8±25.3μmol/ L，TAE后为96.1±27.7μmol/ L（P = .095）。栓塞前后的eGFR为75.2±26.5 mL / min / 1.73 m 2 和72.5±26.2 mL / min / 1.73 m 2 （P = .16）。随访期间未观察到严重并发症。这项回顾性研究表明，TAE治疗医源性肾动脉假性动脉瘤和/或动静脉瘘是安全的，并具有较高的技术和临床成功率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号